Frontiers in Immunology (Sep 2023)
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
- Olaf Penack,
- Olaf Penack,
- Christophe Peczynski,
- Christophe Peczynski,
- Christophe Peczynski,
- Christian Koenecke,
- Christian Koenecke,
- Emmanuelle Polge,
- Emmanuelle Polge,
- Emmanuelle Polge,
- Robin Sanderson,
- Ibrahim Yakoub-Agha,
- Nathalie Fegueux,
- Michael Daskalakis,
- Michael Daskalakis,
- Matthew Collin,
- Peter Dreger,
- Nicolaus Kröger,
- Urs Schanz,
- Adrian Bloor,
- Arnold Ganser,
- Caroline Besley,
- Caroline Besley,
- Gerald G. Wulf,
- Urban Novak,
- Ivan Moiseev,
- Ivan Moiseev,
- Hélène Schoemans,
- Hélène Schoemans,
- Grzegorz W. Basak,
- Grzegorz W. Basak,
- Christian Chabannon,
- Christian Chabannon,
- Anna Sureda,
- Anna Sureda,
- Bertram Glass,
- Bertram Glass,
- Zinaida Peric,
- Zinaida Peric
Affiliations
- Olaf Penack
- Medical Clinic, Department for Haematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin, Germany
- Olaf Penack
- EBMT Transplant Complications Working Party, Paris, France
- Christophe Peczynski
- EBMT Transplant Complications Working Party, Paris, France
- Christophe Peczynski
- EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, Paris, France
- Christophe Peczynski
- INSERM UMR-S 938, Sorbonne University, Paris, France
- Christian Koenecke
- EBMT Transplant Complications Working Party, Paris, France
- Christian Koenecke
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
- Emmanuelle Polge
- EBMT Transplant Complications Working Party, Paris, France
- Emmanuelle Polge
- EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, Paris, France
- Emmanuelle Polge
- INSERM UMR-S 938, Sorbonne University, Paris, France
- Robin Sanderson
- Kings College Hospital, Departement of Haematological Medicine, London, United Kingdom
- Ibrahim Yakoub-Agha
- CHU de Lille, Univ Lille, INSERM U1286, Infinite, Lille, France
- Nathalie Fegueux
- CHU Lapeyronie, Département d`Hématologie Clinique, Montpellier, France
- Michael Daskalakis
- Department of Hematology, University Hospital Bern, Bern, Switzerland
- Michael Daskalakis
- 0Department of Oncology, University Hospital Bern, Bern, Switzerland
- Matthew Collin
- 1Adult HSCT Unit, Northern Centre for Bone Marrow Transplantation, Newcastle upon Tyne, United Kingdom
- Peter Dreger
- 2Department of Hematology, University of Heidelberg, Heidelberg, Germany
- Nicolaus Kröger
- 3Bone Marrow Transplantation Centre, University Hospital Eppendorf, Hamburg, Germany
- Urs Schanz
- 4Clinic of Hematology, University Hospital, Zurich, Switzerland
- Adrian Bloor
- 5Christie NHS Trust Hospital, Adult Leukaemia and Bone Marrow Transplant Unit, Manchester, United Kingdom
- Arnold Ganser
- 6Department of Haematology, Hemostasis, Oncology, Hannover Medical School, Hannover, Germany
- Caroline Besley
- 7Department of Paediatric Oncology, Bristol Royal Hospital for Children, Bristol, United Kingdom
- Caroline Besley
- 8Department of BMT, Bristol Royal Hospital for Children, Bristol, United Kingdom
- Gerald G. Wulf
- 9Universitaetsmedizin Goettingen, Klinik für Hämatologie und Medizinische Onkologie, Göttingen, Germany
- Urban Novak
- 0Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- Ivan Moiseev
- EBMT Transplant Complications Working Party, Paris, France
- Ivan Moiseev
- 1Department of Hematology, First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russia
- Hélène Schoemans
- EBMT Transplant Complications Working Party, Paris, France
- Hélène Schoemans
- 2Department of Hematology, University Hospitals Leuven and KU Leuven, Leuven, Belgium
- Grzegorz W. Basak
- EBMT Transplant Complications Working Party, Paris, France
- Grzegorz W. Basak
- 3Department of Hematology, Oncology and Internal Medicine, The Medical University of Warsaw, Warsaw, Poland
- Christian Chabannon
- 4EBMT Cellular Therapy and Immunobiology Working Party, Leiden, Netherlands
- Christian Chabannon
- 5Institut Paoli-Calmettes Comprehensive Cancer Centre, Inserm CBT-1409, Aix-Marseille Université, Marseille, France
- Anna Sureda
- 6Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, Barcelona, Spain
- Anna Sureda
- 7Institut de Ciències Biomèdiques de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain
- Bertram Glass
- 8EBMT Lymphoma Working Party, Leiden, Netherlands
- Bertram Glass
- 9Department of Hematology, Oncology, and Tumor ImmunologyKlinikum Berlin-Buch, Helios, Berlin, Germany
- Zinaida Peric
- EBMT Transplant Complications Working Party, Paris, France
- Zinaida Peric
- 0University Hospital Centre Zagreb and School of Medicine, University of Zagreb, Zagreb, Croatia
- DOI
- https://doi.org/10.3389/fimmu.2023.1252811
- Journal volume & issue
-
Vol. 14
Abstract
We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.
Keywords
